ProQR Therapeutics N.V [PRQR] stock is trading at $2.16, up 6.40%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The PRQR shares have gain 14.29% over the last week, with a monthly amount glided 29.34%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Evercore ISI started tracking the stock with Outperform rating on April 29, 2025, and set its price target to $5. On March 10, 2025, upgrade upgraded it’s rating to Buy but maintained its price target of $4 on the stock. Oppenheimer started tracking the stock assigning a Outperform rating and suggested a price target of $15 on January 10, 2025. Raymond James upgraded its rating to a Strong Buy and raised its price target to $14 on October 29, 2024. Chardan Capital Markets upgraded its rating to Buy for this stock on November 08, 2023, but kept the price target unchanged to $2. In a note dated March 30, 2023, JMP Securities upgraded an Mkt Outperform rating on this stock and boosted its target price from $1.50 to $5.
ProQR Therapeutics N.V [PRQR] stock has fluctuated between $1.07 and $4.62 over the past year. Currently, Wall Street analysts expect the stock to reach $3.63 within the next 12 months. ProQR Therapeutics N.V [NASDAQ: PRQR] shares were valued at $2.16 at the most recent close of the market. An investor can expect a potential return of 68.06% based on the average PRQR price forecast.
Analyzing the PRQR fundamentals
ProQR Therapeutics N.V [NASDAQ:PRQR] reported sales of 20.36M for the trailing twelve months, which represents a drop of -1.53%. Gross Profit Margin for this corporation currently stands at 0.96% with Operating Profit Margin at -1.76%, Pretax Profit Margin comes in at -1.6%, and Net Profit Margin reading is -1.59%. To continue investigating profitability, this company’s Return on Assets is posted at -0.2, Equity is -0.54 and Total Capital is -0.28. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.21.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.04 points at the first support level, and at 1.92 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.24, and for the 2nd resistance point, it is at 2.32.
Ratios To Look Out For
For context, ProQR Therapeutics N.V’s Current Ratio is 4.10. In addition, the Quick Ratio stands at 4.10 and the Cash Ratio stands at 3.93. Considering the valuation of this stock, the price to sales ratio is 11.16, the price to book ratio is 2.67.
